Are there specific aspects of care that need to be considered for young male patients with schizophrenia?

Professors John Kane, Philip Gorwood and David Castle look at the issues facing younger male patients with schizophrenia, in particular managing adverse effects and substance use.

The views and opinions expressed in this video do not necessarily reflect those of Lundbeck and Otsuka.

Page: AU-ABIM-0581. September 2024. Video: AU-ABIM-0538. April 2024.

  • Box
    Body

    Abilify Maintena PBS Information: Authority required (STREAMLINED). Code: 4246 for schizophrenia.
    This product is not listed on the PBS for the treatment of bipolar 1 disorder.

  • text
    Body

    Please review Approved Product Information before prescribing.
    Product Information is available by calling Lundbeck on 1300 721 277 or by clicking:

    Abilify Maintena PI

    Abilify Maintena is a registered trademark of Otsuka Pharmaceutical Co., Ltd. Abilify Maintena is co-commercialised by Lundbeck Australia and Otsuka Australia Pharmaceutical Pty Limited.

     

     

Related

Related